A$0.585 0.0 0.0%
Last Trade - 4:38am
| Market Cap | £50.2m |
| Enterprise Value | £60.2m |
| Revenue | £12.3m |
| Position in Universe | 865th / 1842 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.68 | 10.6 | 22.3 | 46.6 | 54.8 | 22.1 | 63.0 | 72.0 | +43.1% | ||
| +133.3 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Palla Pharma Limited, formerly TPI Enterprises Limited, is an Australia-based company, which is engaged in the manufacture and supply of alkaloids to international markets. The Company's segment is supplying narcotic raw materials (NRM), including morphine and thebaine to the active pharmaceutical ingredient sector. The Company uses its technology for solvent free extraction of alkaloids from opium poppies. It sources its raw materials from Australian poppy growers in Tasmania and Victoria. The Company assists customers with NRM conversions, such as methylation and oxidiation reactions. The Company sells and exports culinary poppy seed throughout Australia and around the world. The Company focuses on manufacture and supply of the products, including concentrate of poppy straw (oripavine), concentrate of poppy straw (thebaine), concentrate of poppy straw (morphine), concentrate of poppy straw (codeine), technical oripavine, technical codeine, noscapine and certified alkaloid impurities.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | February 5, 2004 |
| Public Since | August 13, 2015 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 153,947,977 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Twr 4 727 Collins St, MELBOURNE, 3008, Australia |
| Web | https://www.tpienterprises.com/ |
| Phone | +61 3 93010800 |
| Contact | () |
| Auditors | KPMG |
As of 4:38am, shares in Palla Pharma are trading at A$0.585, giving the company a market capitalisation of £50.2m. This share price information is delayed by 15 minutes.
Shares in Palla Pharma are currently trading at A$0.585 and the price has moved by -24.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Palla Pharma price has moved by -30.58% over the past year.
Of the analysts with advisory recommendations for Palla Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Palla Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Palla Pharma is scheduled to issue upcoming financial results on the following dates:
Palla Pharma does not currently pay a dividend.
Palla Pharma does not currently pay a dividend.
Palla Pharma does not currently pay a dividend.
To buy shares in Palla Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Palla Pharma are currently trading at A$0.585, giving the company a market capitalisation of £50.2m.
Here are the trading details for Palla Pharma:
Based on an overall assessment of its quality, value and momentum, Palla Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Palla Pharma are currently priced at A$0.585. At that level they are trading at 80.34% discount to the analyst consensus target price of 0.00.
Analysts covering Palla Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Palla Pharma. Over the past six months, the relative strength of its shares against the market has been -26.21%. At the current price of A$0.585, shares in Palla Pharma are trading at -19% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Palla Pharma.
Palla Pharma's management team is headed by:
Here are the top five shareholders of Palla Pharma based on the size of their shareholding:
